Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition

Fig. 6

BRCA2 deficiency increases sensitivity of Cyst(e)inase treatment. A Schematics of BRCA2 knockdown and Cyst(e)inase treatment procedure; B HMVP2, 22Rv1 and PC3 cells were transfected with BRCA2 siRNA (ON-TARGET plus siRNA: SMART pool; Cat# L-003462–00-0005, and L-042993–00-0005) for 72 h and BRCA2 knockdown was determined by Western blot (α-tubulin as loading control); C Representative image of γH2AX/53BP1 co-localization in BRCA2 proficient and deficient (siRNA BRCA2) cells after treatment with vehicle or Cyst(e)inase (50 nM). D Percent of BRCA2 proficient and deficient cells positive for co-localization of γH2AX with 53BP1; E BRCA2 proficient and deficient cells were treated with different concentration of Cyst(e)inase for 72 h and cell viability was measured by crystal violet assay. More than 110 cells were scored from each group for γH2AX/53BP1 co-localization. *P < 0.05, **P < 0.01 and ****P < 0.0001; Student’s t test (D) or One way ANOVA followed by Dunnett's multiple comparison test (E). n = 3 independent experiments

Back to article page